ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Discovery of cerebrospinal fluid biomarkers for different dementias using mass spectrometry-based proteomics.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Brain defence by the extracellular matrix protein Cochlin.Communications biology · 2026Article
- Discovery of cerebrospinal fluid biomarkers for different dementias using mass spectrometry-based proteomics.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCommon forms of dementia include Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Disease specific biomarkers are needed for differential disease diagnosis.
methodsWe performed cerebrospinal fluid (CSF) mass spectrometry proteomics on three cohorts (
resultsWe identified and validated 11, 3, and 5 differentially expressed proteins in AD, DLB, and FTD, respectively. Potential disease specific proteins included fructose-bisphosphate aldolase A (ALDOA), L-lactate dehydrogenase A chain (LDHA), malate dehydrogenase, cytoplasmic (MDH1), and phosphoglycerate mutase 1 (PGAM1), which were upregulated in AD and MCI Aβ+ across multiple cohorts and did not display altered levels in DLB and FTD. Validated DLB and FTD proteins were altered in similar directions in other dementia types in at least one other cohort. DISCUSSION: Proteomics identified potential disease specific biomarkers in AD which were already altered in the prodromal stage. Highlights: We studied cerebrospinal fluid (CSF) proteomic alterations in Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD).Proteins with altered CSF levels were associated with immune related processes in AD, DLB, and FTD, glycolytic processes in AD and amyloid-beta positive mild cognitive impairment (MCI Aβ+), and synaptic processes in FTD.MCI Aβ+ and MCI Aβ- displayed divergent proteomic changes, with MCI Aβ+ being more similar to AD, while alterations in MCI Aβ- were difficult to relate to any of the dementias studied.Glycolytic protein levels were specifically upregulated in AD and MCI Aβ+ in our cohorts and in previously published cohorts, while these were unaltered in DLB and FTD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.